Home » Current Affairs In-depths & Editorials » GS2 » Society & Social Justice » Social Justice » Social Sector » Health » Diseases » 93% DPT3 immunisation coverage in 2022: WHO

93% DPT3 immunisation coverage in 2022: WHO

Santhosh Kumar 19/07/2023

93% DPT3 immunisation coverage in 2022: WHO upsc notes
Source: TH
According to World Health Organization (WHO)
India’s coverage rate
For the DPT3 vaccine
Diphtheria, pertussis, and tetanus
Reached an all-time high
Of 93% in 2022
Surpassed the pre-pandemic best
Of 91% in 2019
Showed a significant increase
From 85% recorded in 2021
In the WHO South-East Asia Region
The DPT3 coverage rate
Recovered to pre-pandemic levels
At 91% in 2022
Up from 82% in 2021
Key Findings
The region witnessed improvements
In the coverage of the measles vaccine
Which rose to 92% in 2022
From 86% in 2021
The number of zero-dose children
Halved to 2.3 million in 2022
From 4.6 million in 2021
Number of partially vaccinated children
Decreased to 650,000 in 2022
From 1.3 million in 2021
India and Indonesia
Credited for the region’s strong immunization recoveries
They made significant efforts
To improve vaccination rates
The report highlighted the importance
Of closing gaps in immunization coverage
At the subnational level
To prevent outbreaks
Of vaccine-preventable diseases
About DTP
DTP vaccine
Can prevent diphtheria, tetanus, and pertussis
Diphtheria and pertussis
Spread from person to person
Tetanus
Enters the body through cuts or wounds
DIPHTHERIA (D)
Can lead to difficulty breathing
Heart failure, paralysis, or death
TETANUS (T)
Causes painful stiffening of the muscles
Tetanus can lead to serious health problems
Including being unable to open the mouth
Having trouble swallowing and breathing
Or death
PERTUSSIS (aP)
Also known as “whooping cough”
Can cause uncontrollable, violent coughing
That makes it hard to breathe, eat, or drink
Pertussis can be extremely serious
Especially in babies and young children
Causes pneumonia, convulsions, brain damage, or death
In teens and adults
Can cause weight loss
Loss of bladder control
Passing out, and rib fractures
From severe coughing

If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.

Related Posts

Amyloidosis mind map COntext Scientists from Institute of Advanced Study in Science and Technology, Guwahati (IASST) Under Department of Science and Technology (DST) in North-East India Successfully fabricated 2D protein monolayer Using lysozyme molecules Lysozyme Crucial protein in mucosal secretions Principal component of airway fluid Model protein for understanding diseases like Amyloidosis Understanding Amyloidosis: A Rare Disease with Multi-Organ Impact Amyloidosis characterized by accumulation of amyloid in organs Adversely affects functioning of vital organs Heart, kidneys, liver, spleen, nervous system, digestive tract Leads to multi-organ dysfunction Lysozyme as a Model Protein in Disease Study Lysozyme’s role in studying Amyloidosis Misfolding and agglomeration of lysozyme molecules Implicated in development of Amyloidosis Valuable subject for scientific inquiry Innovative Fabrication of 2D Protein Monolayer Led by Dr. Sarathi Kundu, Associate Professor at IASST Collaboration with junior Research Fellow Himadri Nath Fabrication of 2D protein monolayer Assembling lysozyme molecules at air-water and air-solid interfaces Employed Langmuir-Blodgett (LB) technique Insights into Lysozyme Behavior Study published in RSC Advances under RSC publishers Explored physical properties of lysozyme molecules Compressible behavior of lysozyme monolayers Formation of stripe-like domains with increasing surface pressure Investigated under varying subphase pH conditions Provided insights into structural, conformational changes of lysozyme molecules Applications and Future Implications Closely packed lysozyme monolayers Exciting avenue for studying chemical, physical properties in 2D protein environment Deposited LB films of lysozyme Potential as protein nanotemplates Opportunities for crystallization of proteins of interest

23/11/2023 / Diseases

R21/Matrix-M Malaria Vaccine mind map Recent News WHO Prequalification Eligible for UN procurement Recommended by WHO Strategic Advisory Group of Experts (SAGE) Malaria Policy Advisory Group (MPAG) In October 2023 Why High burden of malaria Especially on African children What Developed by University of Oxford Serum Institute of India Leveraging Novavax technology Efficacy High in children Reduces symptomatic malaria Clinical Trials Phase III In 4 countries Burkina Faso, Kenya, Mali, Tanzania Manufacturing Capacity Serum Institute of India 100 million doses per annum Doubling in next two years Licensing Ghana, Nigeria, Burkina Faso Support European and Developing Countries Clinical Trials Partnership Wellcome Trust European Investment Bank Where Global rollout Who Developers Jenner Institute, Oxford Serum Institute of India Key Individuals Adrian Hill Director, Jenner Institute Adar Poonawalla CEO, Serum Institute of India Recipients Children in malaria-endemic regions How Mass production Affordable cost Global distribution Pros High efficacy Reducing malaria cases Affordable Cost-effective intervention Safety Well-tolerated in trials Impact Public health improvement Challenges Supply and demand challenges Comparing with RTS,S/AS01 vaccine Way Forward Scaling up production Expanding reach

R21/Matrix-M Malaria Vaccine

24/12/2023 / Diseases

Anti biotic resistance UPSC IAS

Antimicrobial Resistance – A Global Threat to Public Health

18/11/2021 / Diseases, Health

aarogya setu app upsc

Aarogya Setu App – Objectives, Working, Concerns

01/05/2020 / Diseases, Science & Technology

Categories: Diseases

Tags: 19.07.2023, Newsbits

Subscribe

0 Comments

Inline Feedbacks

View all comments

X